國家衛生研究院 NHRI:Item 3990099045/10527
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 915975      線上人數 : 1320
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/10527


    題名: Meglitinides increase the risk of hypoglycemia in diabetic patients with advanced chronic kidney disease: A nationwide, population-based study
    作者: Wu, PC;Wu, VC;Lin, CJ;Pan, CF;Chen, CY;Huang, TM;Wu, CH;Chen, L;Wu, CJ;Consortium, The NRPB Kidney
    貢獻者: Division of Health Services and Preventive Medicine
    摘要: The safety of short-acting meglitinides in diabetic patients with advanced chronic kidney disease (CKD) has not been widely reported.Diabetic patients with advanced CKD who had a serum creatinine level of > 6 mg/dL a hematocrit level of <== 28% and received erythropoiesis-stimulating agent treatment between 2000 and 2010, were included in this nationwide study in Taiwan.The outcomes of interest were defined as hypoglycemia and long-term mortality. The risks of hypoglycemia and death were analyzed using Cox proportional hazards models, with end-stage renal disease and anti-diabetic drugs as time-dependent variables.Fresh users and matched non-users of meglitinides (both n = 2,793) were analyzed. The use of meglitinides increased the risk of hypoglycemia (HR, 1.93; 95% CI, 1.56-2.39), as did sulfonylurea and insulin use. The hypoglycemic effect of meglitinides was consistent among patient subgroups stratified by the status of concomitant use of other oral anti-diabetic agents. Concomitant use of meglitinide and insuilin will incresase the hypoglycemic risk. Moreover, it was not the use of meglitinides, but the presence of hypoglycemia that predicted mortality. The function curve showed an insignificant trend towards increased hypoglycemic risk in patients aged > 62 and </= 33 years from the generalized additive model.This study suggests that the use of short-acting meglitinides could be associated with increased risk of hypoglycemia in diabetic patients with advanced CKD, especially in patients aged > 62 and </= 33 years. Meglitinide combined with insulin will increase hypoglycemia in patients with advanced CKD.
    日期: 2017-09
    關聯: Oncotarget. 2017 Sep;8(44):78086-78095.
    Link to: https://doi.org/10.18632/oncotarget.17475
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000412066700183
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85030309241
    顯示於類別:[陳麗光] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB28514729.pdf1070KbAdobe PDF331檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋